5-amino-3-(4-chlorophenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide | 1221069-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩哒嗪类
• 英文名称: 5-amino-3-(4-chlorophenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide
• 英文别名: ATPZ；5-amino-3-(4-chlorophenyl)-4-oxo-N-propan-2-ylthieno[3,4-d]pyridazine-1-carboxamide
• CAS: 1221069-61-9
• 化学式: C₁₆H₁₅ClN₄O₂S
• 分子量: 362.84
• InChiKey: SBBDRSPWLDISOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-amino-3-(4-chlorophenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 、 5-amino-3-(4-fluorophenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylic acid 生成 5-amino-3-(4-fluorophenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide
  参考文献：
  名称：

  AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY

  摘要：

  本发明涉及通过给予I型化合物来抑制患者的tau病变的方法：还描述了新的氨基噻吩吡嗪化合物。

  公开号：

  US20130029983A1
• 作为产物：
  描述：

  ethyl 5-amino-3-(4-chlorophenyl)-4-oxo-3,4-dihydrothieno-[3,4-d]pyridazine-1-carboxylate 在 lithium hydroxide monohydrate 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 水 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 20.0h， 生成 5-amino-3-(4-chlorophenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide
  参考文献：
  名称：

  [EN] AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY
  [FR] INHIBITEURS AMINOTHIÉNOPYRIDAZINIQUES DE L'ASSEMBLAGE DES MICROTUBULES SOUS L'EFFET DE LA PROTÉINE TAU

  摘要：

  公开号：

  WO2011037985A8

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME SONDES D'IMAGERIE DE PATHOLOGIE TAU
  申请人：GE HEALTHCARE LTD

  公开号：WO2013090497A1

  公开（公告）日：2013-06-20

  Pyridazinone compounds of Formula I: (I) wherein: R' is alkyl or Ar, optionally substituted with at least one alkyl, halo¬ gen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, -C(=0)alkyl, -C(=0)aryl, -C(=0)heteroaryl, -C(=0)heterocycloalkyl, - C(=0)heterocycloalkylAr, -C(=0)(CH2)nhalo, -C(=0)(CH2)nheterocyclyl, or -SC^Ar, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH2)nhalo; R 3 and R4 are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

  Formula I中的吡啶嗪酮化合物：（I），其中：R'是烷基或Ar，可选择地取代为至少一个烷基，卤素，羟基，烷氧基，卤代烷氧基，酸，酯，氨基，硝基，酰胺，或烷氧基卤代；2 R独立地是烷基，炔基，酯，氨基，酰胺，酸，芳基，杂环芳基，氨基烷基，-C(=0)烷基，-C(=0)芳基，-C(=0)杂环芳基，-C(=0)杂环烷基，-C(=0)杂环烷基Ar，-C(=0)(CH2)n卤代，-C(=0)(CH2)n杂环基，或-SC^Ar，可选择地取代为至少一个烷基，烷基卤代，卤素，硝基，芳基，杂环芳基，或杂环芳基(CH2)n卤代；R3和R4独立地是氢，烷基，烯基，炔基，芳基，杂环芳基；Ar是芳基，杂环芳基，环烷基，杂环烷基基团；n是0-10之间的整数；或其放射标记衍生物。所述化合物可用作阿尔茨海默病中Tau病理的成像探针。还描述了制备这种化合物的组成物和方法。
• HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY
  申请人：GE HEALTHCARE LIMITED

  公开号：US20150004100A1

  公开（公告）日：2015-01-01

  Pyridazinone compounds of Formula I: (I) wherein: R′ is alkyl or Ar, optionally substituted with at least one alkyl, halogen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, —C(=0)alkyl, —C(=0)aryl, —C(=0)heteroaryl, —C(=0)heterocycloalkyl, —C(=0)heterocycloalkylAr, —C(=0)(CH 2 ) n halo, —C(═O)(CH 2 )nheterocyclyl, or —SĈAr, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH 2 )nhalo; R 3 and R 4 are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

  公式I中的吡啶并酮化合物：(I) 其中：R′是烷基或Ar，可选地被至少一种烷基，卤素，羟基，烷氧基，卤代烷氧基，酸，酯，氨基，硝基，酰胺或烷氧卤代基取代；2R独立地是烷基，炔基，酯，氨基，酰胺，酸，芳基，杂芳基，氨基烷基，-C（= 0）烷基，-C（= 0）芳基，-C（= 0）杂芳基，-C（= 0）杂环烷基，-C（= 0）杂环烷基Ar，-C（= 0）（CH2）n卤代基，-C（═O）（CH2）nheterocyclyl或-SĈAr，可选地被至少一种烷基，烷基卤代基，卤素，硝基，芳基，杂芳基或杂芳基（CH2）n卤代基取代；R3和R4独立地是氢，烷基，烯基，炔基，芳基，杂芳基；Ar是芳基，杂芳基，环烷基，杂环烷基基团；n是0-10的整数；或其放射性标记衍生物。这些化合物可用作阿尔茨海默病中Tau病理学的成像探针。还描述了制备这种化合物的组合物和方法。
• Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation
  作者：Carlo Ballatore、Kurt R. Brunden、Francesco Piscitelli、Michael J. James、Alex Crowe、Yuemang Yao、Edward Hyde、John Q. Trojanowski、Virginia M.-Y. Lee、Amos B. Smith

  DOI：10.1021/jm100138f

  日期：2010.5.13

  Agents capable of preventing the misfolding and sequestration of the microtubule-stabilizing protein tau into insoluble fibrillar aggregates hold considerable promise for the prevention and/or treatment of neurodegenerative tauopathies such as Alzheimer's disease. Because tauopathies are characterized by amyloidosis that is restricted to the central nervous system (CNS), plausible candidate compounds for in vivo evaluation must both prevent tau fibrillization and achieve significant brain levels. Recently, we reported the discovery of the aminothienopyridazine (ATPZ) class of tau aggregation inhibitors and now describe a series of new analogues that are both effective inhibitors of tau fibrillization and display significant brain-to-plasma exposure ratios after administration to mice. Further, two of the most promising examples, 15 and 16, were found to reach significant brain exposure levels following oral administration. Taken together, these results suggest that examples from the ATPZ class hold promise as candidates for in vivo efficacy studies in animal models of neurodegenerative tauopathies.
• [EN] AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY<br/>[FR] INHIBITEURS AMINOTHIÉNOPYRIDAZINIQUES DE L'ASSEMBLAGE DES MICROTUBULES SOUS L'EFFET DE LA PROTÉINE TAU
  申请人：UNIV PENNSYLVANIA

  公开号：WO2011037985A8

  公开（公告）日：2011-06-09
• AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY
  申请人：Ballatore Carlo

  公开号：US20130029983A1

  公开（公告）日：2013-01-31

  The present invention is directed to methods of inhibiting a tauopathy in a patient by administration of a compound of formula I: Novel aminothienopyridazine compounds are also described.

  本发明涉及通过给予I型化合物来抑制患者的tau病变的方法：还描述了新的氨基噻吩吡嗪化合物。